OXTELLAR XR Rx
Generic Name and Formulations:
Oxcarbazepine 150mg, 300mg, 600mg; extended-release tablets.
Supernus Pharmaceuticals, Inc.
Indications for OXTELLAR XR:
Adjunctive therapy in the treatment of partial seizures in adults and in children 6–17yrs of age.
Take on empty stomach. Swallow whole. >17yrs: Initially 600mg once daily for 1 week, then may increase by 600mg/day increments at weekly intervals; usual range 1.2g–2.4g/day. Concomitant antiepileptics: consider initiating at 900mg once daily. Severe renal impairment (CrCl <30mL/min): initially 300mg/day; may increase by 300–450mg/day increments at weekly intervals. ESRD on dialysis: use oxcarbazepine immediate-release. Elderly: initially 300mg or 450mg once daily; may increase by 300–450mg/day increments at weekly intervals. Conversion from oxcarbazepine immediate-release: may need higher doses.
<6yrs: not recommended. 6–17yrs: initially 8–10mg/kg once daily; max 600mg/day in the 1st week, then may increase by 8–10mg/kg/day increments at weekly intervals; usual max 600mg/day. Target maintenance doses (attain over 2–3 weeks): 20–29kg: 900mg/day; 29.1–39kg: 1.2g/day; >39kg: 1.8g/day.
Risk of hyponatremia; monitor if signs/symptoms occur. Discontinue if anaphylaxis or angioedema occurs; do not rechallenge. Carbamazepine hypersensitivity. Evaluate for presence of HLA-B*1502 allele (esp. in Asians), if present avoid use; increased risk of severe dermatological reactions. Suicidal behavior and ideation; monitor. Discontinue if DRESS/multi-organ hypersensitivity occurs. Avoid abrupt withdrawal. Severe hepatic impairment: not recommended. Monitor for seizures during pregnancy and through the postpartum period. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
Antagonized by phenytoin, carbamazepine, phenobarbital, valproic acid; monitor and adjust dose. May decrease effectiveness of hormonal contraceptives, other oral or implant contraceptives; use additional non-hormonal forms. Caution with other drugs known to decrease serum sodium. May affect thyroid (T4) tests.
Dizziness, somnolence, headache, balance disorder, tremor, vomiting, diplopia, asthenia, fatigue; hyponatremia, serious skin reactions (eg, Stevens-Johnson syndrome and toxic epidermal necrolysis); rare: pancytopenia, agranulocytosis, leukopenia (discontinue if occurs).
Renal (primarily), fecal.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|